KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Deferred Revenue (2018 - 2025)

Vir Biotechnology's Current Deferred Revenue history spans 8 years, with the latest figure at $10.1 million for Q2 2025.

  • On a quarterly basis, Current Deferred Revenue fell 39.47% to $10.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $10.1 million, a 39.47% decrease, with the full-year FY2024 number at $12.6 million, down 80.5% from a year prior.
  • Current Deferred Revenue hit $10.1 million in Q2 2025 for Vir Biotechnology, down from $11.9 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for VIR hit a ceiling of $262.9 million in Q1 2021 and a floor of $10.1 million in Q2 2025.
  • Historically, Current Deferred Revenue has averaged $48.0 million across 5 years, with a median of $16.2 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 5148.08% in 2021 and later crashed 94.1% in 2022.
  • Tracing VIR's Current Deferred Revenue over 5 years: stood at $98.2 million in 2021, then crashed by 84.2% to $15.5 million in 2022, then surged by 317.95% to $64.9 million in 2023, then plummeted by 80.5% to $12.6 million in 2024, then fell by 20.07% to $10.1 million in 2025.
  • Business Quant data shows Current Deferred Revenue for VIR at $10.1 million in Q2 2025, $11.9 million in Q1 2025, and $12.6 million in Q4 2024.